Anlon H1 FY27 Revenue More Than Doubles, EBITDA Margin Falls
Key highlights
- Anlon Healthcare's consolidated H1 FY27 revenue rose 125.9% year on year to Rs 193.172 crore.
- H1 FY27 EBITDA increased 104.7% to Rs 40.832 crore, while EBITDA margin declined to 21.1% from 23.3%.
- H1 FY27 PAT grew 97.9% to Rs 25.459 crore, and earnings per share doubled to Rs 0.48.
- Q2 FY27 EBITDA margin improved to 23.9% from 17.8% in Q1 FY27, but remained below 26.3% in Q2 FY26.
powered by IRIS

Anlon Healthcare Ltd reported consolidated H1 FY27 revenue of Rs 193.172 crore, up 125.9% from Rs 85.499 crore a year earlier. Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 104.7% to Rs 40.832 crore, but EBITDA margin declined to 21.1% from 23.3%; profit after tax (PAT) increased 97.9% to Rs 25.459 crore.
Know Anlon Healthcare inside out
Results, valuation, peers and who's buying, in one view.
What did Anlon report for H1 FY27?
Anlon reported higher revenue and profit in H1 FY27, although sales grew faster than gross profit, EBITDA and PAT. Revenue increased by Rs 107.673 crore year on year, compared with a Rs 25.900 crore increase in gross profit, a Rs 20.883 crore increase in EBITDA and a Rs 12.595 crore increase in PAT.
The reported comparison shows that the 125.9% revenue increase was ahead of the 91.5% gross-profit increase and the 104.7% EBITDA increase. Earnings per share doubled to Rs 0.48 in H1 FY27 from Rs 0.24 in H1 FY26, while profit before tax rose 112.8% to Rs 37.134 crore.
Why did Anlon's margins decline in H1 FY27?
Anlon's H1 FY27 gross profit margin fell to 28.1% from 33.1%, EBITDA margin fell to 21.1% from 23.3%, and PAT margin fell to 13.2% from 15.0%. The figures show that absolute profits increased, but the proportion of revenue retained at gross-profit, EBITDA and PAT levels declined from H1 FY26.
Purchase of services rose to Rs 138.956 crore in H1 FY27 from Rs 57.181 crore in H1 FY26, an increase of Rs 81.775 crore against a Rs 107.673 crore increase in revenue. Employee expenses increased to Rs 4.541 crore from Rs 2.287 crore, and other expenses rose to Rs 8.844 crore from Rs 6.082 crore. The presentation does not attribute the margin movement to a particular cost item, business or product category.
The margin movement was different across the two FY27 quarters. Gross margin improved to 31.0% in Q2 FY27 from 24.5% in Q1 FY27, EBITDA margin rose to 23.9% from 17.8%, and PAT margin increased to 16.3% from 9.5%. However, each Q2 FY27 margin remained below Q2 FY26 levels of 36.9%, 26.3% and 17.8%, respectively.
How did Anlon perform in Q2 FY27?
Anlon recorded Q2 FY27 revenue of Rs 105.610 crore, up 102.3% from Rs 52.201 crore in Q2 FY26 and 20.6% from Rs 87.563 crore in Q1 FY27. Q2 gross profit was Rs 32.735 crore, EBITDA was Rs 25.241 crore and PAT was Rs 17.178 crore, all above Q1 FY27 figures of Rs 21.482 crore, Rs 15.591 crore and Rs 8.281 crore.
Against Q2 FY26, EBITDA increased from Rs 13.710 crore to Rs 25.241 crore and PAT rose from Rs 9.317 crore to Rs 17.178 crore. The quarterly-financial-highlights page states EBITDA growth of 84.1%, while the detailed income statement gives 84.7% using the same EBITDA amounts. The detailed statement reports Q2 FY27 profit before tax of Rs 23.475 crore, up from Rs 12.447 crore a year earlier.
Q2 FY27 finance cost was Rs 86.2 lakh, compared with Rs 83.8 lakh in Q2 FY26 and Rs 92.5 lakh in Q1 FY27. Depreciation was Rs 95.0 lakh, versus Rs 45.2 lakh a year earlier and Rs 106.6 lakh in Q1 FY27. Tax expense rose to Rs 6.297 crore from Rs 3.130 crore alongside the increase in profit before tax.
Got a follow-up? Ask IRIS
Which businesses generated Anlon revenue in H1 FY2027?
Anlon accounted for 44.6% of group revenue in H1 FY2027, while Apiqo Organics Pvt Ltd represented 43.7% and Bizotic Lifescience Pvt Ltd accounted for 11.7%. The two largest contributors were separated by 0.9 percentage points, and together represented 88.3% of reported group revenue.
The presentation identifies Anlon as a pharmaceutical business with a focused portfolio of active pharmaceutical ingredients and intermediates. It describes Apiqo Organics as an industrial and fine chemicals platform with installed capacity of 700-800 metric tonnes per annum, while Bizotic Lifescience is an active pharmaceutical ingredient manufacturing facility with capacity of 300-400 metric tonnes per annum.
The presentation supplies no H1 FY26 company-level revenue split, so it does not show how the 44.6%, 43.7% and 11.7% contributions changed year on year. It also does not provide a product-level revenue allocation for Apiqo Organics or Bizotic Lifescience, limiting direct analysis of whether the group mix contributed to the decline in EBITDA margin from 23.3% to 21.1%.
What does Anlon's product mix show?
Intermediates generated 81.1% of Anlon revenue in H1 FY2027, compared with 17.1% for active pharmaceutical ingredients, 1.5% for nutraceuticals and 0.3% for other categories. Intermediates therefore exceeded the active pharmaceutical ingredient share by 64.0 percentage points within Anlon's reported revenue mix.
The 81.1% intermediate share applies to Anlon's revenue, not automatically to all consolidated H1 FY27 revenue of Rs 193.172 crore. Apiqo Organics and Bizotic Lifescience together represented 55.4% of group revenue, and the presentation provides neither their category-level splits nor an equivalent H1 FY26 product mix for Anlon.
Conclusion
Anlon's H1 FY27 results show rapid expansion in consolidated revenue, with sales reaching Rs 193.172 crore and PAT reaching Rs 25.459 crore. Yet gross profit, EBITDA and PAT all grew more slowly than revenue, resulting in lower reported margins than in H1 FY26. Q2 FY27 also showed a sequential recovery in each of the three stated margin measures from Q1 FY27.
What to watch next is whether Q2 FY27's gross margin of 31.0% and EBITDA margin of 23.9% are sustained after the Q1 FY27 levels of 24.5% and 17.8%. The presentation provides no margin target or prior-period company and product-mix comparisons, leaving the specific drivers of the H1 FY27 margin decline unresolved.


